Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 27Philadelphia Chromosome 3Leukemia, Myeloid, Chronic-Phase 3Leukemia 3Blast Crisis 3Bronchiolitis Obliterans Syndrome 2Translocation, Genetic 1Pathologic Processes 1Neoplasms by Histologic Type 1Myeloproliferative Disorders 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Myeloid 1Hematologic Diseases 1Breast Neoplasms 1Bone Marrow Diseases 1

Interventions

Imatinib Mesylate 9fludarabine 5Whole-Body Irradiation 5Tacrolimus 5Mycophenolic Acid 5Cyclophosphamide 5Busulfan 5ponatinib 4nilotinib 4fludarabine phosphate 4Peripheral Blood Stem Cell Transplantation 4Cytarabine 3Bone Marrow Transplantation 3venetoclax 2thymoglobulin 2asciminib 2Sirolimus 2Patient Reported Outcome Measures 2Methotrexate 2Mesna 2Melphalan 2Dasatinib 2Behavior Therapy 2Azacitidine 24-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide 2zileuton 1spartalizumab 1sabatolimab 1nicotinamide-beta-riboside 1methanesulfonic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Myeloid × bosutinib × Myeloid × Clear all
NCT02130557 2021-05-18

A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Pfizer

Phase 3 Completed
536 enrolled 24 charts 1 FDA
MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Bone Marrow Diseases, Hematologic Diseases, Leukemia, Leukemia, Myeloid, Neoplasms by Histologic Type, Pathologic Processes, Philadelphia Chromosome, Translocation, Genetic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡